Identification and Characterization of Plasmin-Independent Thrombolytic Enzymes

Circ Res. 2021 Feb 5;128(3):386-400. doi: 10.1161/CIRCRESAHA.120.317245. Epub 2020 Dec 9.

Abstract

Rationale: Current thrombolytic agents activate plasminogen to plasmin which triggers fibrinolysis to dissolve thrombi. Since plasmin is a nonspecific proteolytic enzyme, all of the current plasmin-dependent thrombolytics lead to serious hemorrhagic complications, demanding a new class of fibrinolytic enzymes independent from plasmin activation and undesirable side effects. We speculated that the mammalian version of bacterial heat-shock proteins could selectively degrade intravascular thrombi, a typical example of a highly aggregated protein mixture.

Objective: The objective of this study is to identify enzymes that can dissolve intravascular thrombi specifically without affecting fibrinogen and fibronectin so that the wound healing processes remain uninterrupted and tissues are not damaged. In this study, HtrA (high-temperature requirement A) proteins were tested for its specific proteolytic activity on intravascular thrombi independently from plasmin activation.

Methods and results: HtrA1 and HtrA2/Omi proteins, collectively called as HtrAs, lysed ex vivo blood thrombi by degrading fibrin polymers. The thrombolysis by HtrAs was plasmin-independent and specific to vascular thrombi without causing the systemic activation of plasminogen and preventing nonspecific proteolysis of other proteins including fibrinogen and fibronectin. As expected, HtrAs did not disturb clotting and wound healing of excised wounds from mouse skin. It was further confirmed in a tail bleeding and a rebleeding assay that HtrAs allowed normal clotting and maintenance of clot stability in wounds, unlike other thrombolytics. Most importantly, HtrAs completely dissolved blood thrombi in tail thrombosis mice, and the intravenous injection of HtrAs to mice with pulmonary embolism completely dissolved intravascular thrombi and thus rescued thromboembolism.

Conclusions: Here, we identified HtrA1 and HtrA2/Omi as plasmin-independent and highly specific thrombolytics that can dissolve intravascular thrombi specifically without bleeding risk. This work is the first report of a plasmin-independent thrombolytic pathway, providing HtrA1 and HtrA2/Omi as ideal therapeutic candidates for various thrombotic diseases without hemorrhagic complications.

Keywords: fibrinolysis; myocardial infarction; plasminogen; proteolysis; thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Female
  • Fibrin / metabolism*
  • Fibrinolysis / drug effects*
  • Fibrinolytic Agents / pharmacology*
  • Fibrinolytic Agents / toxicity
  • Hemorrhage / chemically induced
  • High-Temperature Requirement A Serine Peptidase 1 / pharmacology*
  • High-Temperature Requirement A Serine Peptidase 1 / toxicity
  • High-Temperature Requirement A Serine Peptidase 2 / pharmacology*
  • High-Temperature Requirement A Serine Peptidase 2 / toxicity
  • Humans
  • Kinetics
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Pulmonary Embolism / blood
  • Pulmonary Embolism / drug therapy*
  • Pulmonary Embolism / enzymology
  • Recombinant Proteins / pharmacology
  • Thrombosis / blood
  • Thrombosis / drug therapy*
  • Thrombosis / enzymology
  • Wound Healing / drug effects

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • Fibrin
  • High-Temperature Requirement A Serine Peptidase 1
  • High-Temperature Requirement A Serine Peptidase 2